🏛️ Verified NIH Record • Updated 2026-05-13
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer (NCT05574101)
A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Response-Adapted Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
Who can join: Review the eligibility criteria below.
Location: University of Colorado (Data Collection Only) — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of Colorado (Data Collection Only) — Aurora, Colorado
- Moffitt Cancer Center (Data Collection Only) — Tampa, Florida
- Memorial Sloan Kettering Cancer Center at Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) — Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (All protocol activities) — Rockville Centre, New York
- Cleveland Clinic (Data Collection Only) — Cleveland, Ohio
- Fox Chase Cancer Center (Data Collection Only) — Philadelphia, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- University of Washington (Data Collection Only) — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cutaneous Squamous Cell Carcinoma
- Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer — La Jolla, California
- A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma — Albury, New South Wales
- Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Gilbert, Arizona
- Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma — Houston, Texas
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy — Boston, Massachusetts
Explore by condition: All Cutaneous Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.